Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis. In recent years the surge of immunotherapy has given cancer sufferers new hope.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64826-issels-recurrent-lung-cancer-responds-to-integrative-immunotherapy
Nearly 90 percent of children and adults with a highly aggressive form of acute lymphoblastic leukemia (ALL) showed no evidence of cancer after receiving a novel, personalized cell therapy that reprograms a patient’s immune system. In pilot studies of bioengineered T cells that attack leukemia, 24 of 27 patients (89%) experienced complete responses within 28 days after treatment. In all, 27 patients received the treatment--22 children treated at The Children’s Hospital of Philadelphia and five adults treated at the Hospital of the University of Pennsylvania.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64394-chop-penn-harness-engineered-t-cells-eliminate-tumors-in-blood-leukemia
In recent years there has been a shift in the understanding of cancer. Immunotherapy with vaccines has been emerging as the most promising direction towards a decisive improvement of treatment outcomes.
The Dendritic Cell Vaccine has received FDA approval for prostate cancer and trials are now under way for a variety of other cancers. These vaccines are usually administered on their own.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64654-issels-integrative-immunotherapy-for-standard-therapy-resistant-cancers
Cricket Communications, Inc. today announced the launch of the ZTE Source, a multimedia powerhouse and the company’s latest 4G LTE smartphone. Featuring a 4.5-inch video graphic display and 5-megapixel (MP) camera, the ZTE Source is perfect for video, photography and music enthusiasts. The ZTE Source will be available at Cricket company-owned stores, dealers and at www.mycricket.com starting Sunday, October 20, 2013, for $219.99 (MSRP).
To view Multimedia News Release, go to http://www.multivu.com/mnr/56768-cricket-launches-4g-lte-zte-source-45-dollars-unlimited-talk
Pre-order now at: http://www.splintercell.com/preorder Tom Clancy's Splinter Cell Blacklist offers two player CO OP mode with 4 mission types, 14 maps with 2 player split-screen. Play
as Sam Fisher or Isaac Briggs (a CIA operative) and work as a duo :
help your teammate access parts of the maps you couldn't access on your
own, create your own tactics depending on your Play Style and watch
each other's back as you complete missions. YOUR RULES. YOUR WAY Official website: http://splintercell.ubi.com/blacklist/ Facebook page: https://www.facebook.com/splintercell Twitter: https://twitter.com/splintercell https://plus.google.com/115575648611906695782/posts Splinter Cell Blacklist will be released on Xbox 360, Playstation 3, PC and WiiU. Release dates: US: August 20th 2013, EU: August 22nd 2013, UK: August 23rd 2013
http://acisni.com/ From AcisNI.com
Find out how cell phone spy software can help improve your business.
Everything from advanced monitoring of employees to security features
to safeguard information.
Daimler AG, Ford Motor Company and Nissan Motor Co., Ltd., have signed a unique three-way agreement to accelerate the commercialization of fuel cell electric vehicle (FCEV) technology.
The goal of the collaboration is to jointly develop a common fuel cell electric vehicle system while reducing investment costs associated with the engineering of the technology. Each company will invest equally towards the project. The strategy to maximize design commonality, leverage volume and derive efficiencies through economies of scale will help to launch the world’s first affordable, mass-market FCEVs as early as 2017.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58680-renault-nissan-daimler-ford-partnership
BlackBerry Bold Touch 9900/Magnum (Unlocked Quadband) GSM Cell Phone Only 10.5mm thick, with a stainless steel frame and an attractive glass weave battery cover, the new Bold is a hybrid device, boasting both a 640x480 pixel capacitive touch screen and a full Qwerty keyboard. Underneath the skin, it’s a modern smartphone with a 1.2 GHz ARM processor and 768MB of RAM. The Bold also has 8GB of flash storage (expandable with up to 32GB of microSD cards).
By reprogramming a 7–year–old girl’s own immune cells to attack an aggressive form of childhood leukemia, a pediatric oncologist has achieved a complete response in his patient, who faced grim prospects when she relapsed after conventional treatment. The innovative experimental therapy used bioengineered T cells, custom–designed to multiply rapidly in the patient, and then destroy leukemia cells. After the treatment, the child’s doctors found that she had no evidence of cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/50777-chop-engineered-immune-t-cell-therapy-anticancer-effect-in-children
We\'re Hub Innovations, a consumer products company born with the mission of developing unique, innovative products that enhance the user\'s experience with their mobile devices. Design, functionality and simplicity is what we live by.
From cell phones to tablets and everything in between, Hub Innovations is focused on developing solutions to help consumers run their personal and professional lives more efficiently. From running a fast-growing national distributor of high quality agrochemicals to pioneering nation-wide retail vaccination programs.
Sutter Neuroscience Institute, a recognized Center of Excellence, and CBR (Cord Blood Registry), the world’s largest stem cell bank, are launching the first FDA- approved clinical trial to assess the use of a child’s own cord blood stem cells to treat select patients with autism. This first-of-its-kind placebo controlled study will evaluate the ability of an infusion of cord blood stem cells to help improve language and behavior. The study is in conjunction with the Sutter Institute for Medical Research.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57707-cord-blood-registry-stem-cell-trials-child-autism
